what is your point? they are simply saying they want to see an abstract of what is going to be presented. they are not judging/determining whether to accept abstracts based on projections of what might be available for presentation
an abstract in hand is worth more than two in the bush
interesting that your respect for 'bashers' is such that you rely on them to make your investment decisions -- but, but, but isn't that what the pumphouse gang was saying when agen was so much higher?
and, isn't it true that you pompom pumping cheerleaders have been in hyper-drive as long as anyone can remember, regardless of news, facts, or figures?
suggest you start doing some real diligence on agen, and to start paying attention to folks like squiggle who are presenting the unvarnished inconvenient truth
the 'expectations' reference was in regards to post subject lines such as the one below from this afternoon, and posts from yourself and others suggesting trial results will be presented...
DCVAX-DIRECT ASCO Abstract, is it going to be a double, triple, or quadruple event?
by greatdayisback2013 • 3 hours ago
the presentation is going to focus on design and technology. it will not, because it cannot, provide any 'update' on anything except maybe for enrollment. the following from the ASCO site pertains to abstracts for trials in progress, and those who are expecting more need to read the last sentence...
Trials in Progress
ASCO recognizes the importance of bringing together researchers to discuss ongoing trials. The Trials in Progress abstracts provide an opportunity for members of the research community to present ongoing trials, foster collaboration, and discuss correlatives and novel trial designs. In addition, the Trials in Progress abstracts presented in the general poster session highlight the transition of emerging biologic pathways and new agents into the clinic—providing "coming attractions" for oncologists in clinical practice.
All phases of clinical research (phases I to III, supportive care, nonpharmacologic interventions) may be considered for inclusion in a Trials in Progress abstract submission. Trials submitted to this session are ongoing and have not reached prespecified endpoints for analysis. As such, inclusion of results would be improper and is strictly forbidden.
probably also why insiders have not bought a single share of this company which means they have NO stake in it since they are paid unusually high current salaries (over $1 million for the husband/wife team) such that it cannot be said they are deferring compensation
see, they were the loudest and dumbest pompom pumpering cheerleaders helping the seeking alfalfa fool artificially inflate ipci and and set everything up for this 'fall' which is really just a return to sanity
now that people see there was no $15-20 million upfront payment from Par, and see focalin sales dropping after initial stocking, and know that sales will drop much more after the 180 day exclusive sales period ends in May, and learn that Par has rights to market its own generic version using different technology -- well, as the truth takes hold, some of the gullible are leaving and some of the newbies are avoiding and the stock is settling in to a more realistic price point
their ownership interest came and comes at the expense of other shareholders
everything in the pipeline is at a very early stage, particularly anything from antibody
stock got juiced on high expectations for phase III trials but those bombed big
2014 and a good part of 2015 is essentially a dead zone for agen shareholders
and, revenue sharing is NOT specified for ipci -- indeed, there is acknowledgement that Par was already working on its own version using different technology and that Par is entitled to proceed
it is there for all to read, it is on file with the SEC
newbies, do not believe the creative pompom pumping nonsense that spews from the self-serving cheerleaders of this board
don't understand the rationale for this proposed quid pro quo but, regardless, have real doubt you can follow through, and suspect a part of you would be hoping that it finishes closer to a buck than a fin
all they need is agreement with manufacturer of branded drug
it's right there for all you pumpers to read, provided you can put down the pompoms long enough
question -- who always claims it is a conspiracy or some skullduggery whenever the stock goes down but never when it goes up?
answer -- this board's resident resolute cheerleaders who refuse to believe inconvenient truths
folks, they unloaded over two million shares in spite of focalin approval
stop listening to the mindless cheerleaders here, and read the SEC filings
need to remind folks that you were also a big buyer of GALE right at it's peak in January which puts you down over 70 percent on that one
you might have a following among shorts by now
based on what criteria?
just because they have a lot of players on the bench doesn't mean any of them can hit the ball, and their record so far has not been good
and now that the biggies so many were anticipating have already failed there is a long wait before anything potentially significant can even happen
nasdaqdotcommie updates the short position every two weeks
shows it reaching a new high as of 3/31
shorts are generally more knowledgeable and intuitive
BTW, you can also find institutional ownership up to the most recent quarter at that site
shows institutions dumped over half their position last quarter (over two million shares), apparently they were not much impressed with focalin being approved
but, of course, the cheerleaders here will challenge those numbers and also challenge the wisdom of shorts and institutions -- all the while wondering why the stock has been going down and becoming ever more inventive with their conspiracy theories
financial statement shows an increase of $4.8 million but that was due entirely to selling $4.9 million in stock, which resulted in over 30 percent dilution
and ipci has more stock to sell -- which sounds like a good strategy given that ipci has a negative tangible net worth
they also know that May is coming and sales will drop considerably when the exclusive sales window ends
the PAR payments do NOT coincide with ipci's quarter
look to the February headlines and note ipci reported a $3.1 million payment from PAR for December and 12 days of November -- divide that by 33 days and you will get $94k/day
are you now sure where that number came from? can any of you cheerleaders see the truth through all those pompoms being pumped so high?
not sure why folks keep saying otherwise
sales have clearly fallen since initial stocking
and sales absolutely will fall further after ipci loses exclusivity in May
then again, maybe threemonths knows of a secret $15-20 milestone payment last quarter from PAR...